K Pharma,Inc. Logo

K Pharma,Inc.

Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.

4896 | T

Overview

Corporate Details

ISIN(s):
JP3280900006
LEI:
Country:
Japan
Address:
港区六本木七丁目7番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

K Pharma, Inc. is a biotechnology company established as a spin-off from the Keio University School of Medicine to commercialize research in induced pluripotent stem (iPS) cell technology. The company engages in the research, development, manufacturing, and sale of pharmaceuticals and regenerative medicine products. Its business is centered on two key areas: iPS drug discovery, which utilizes disease-specific iPS cells to develop new therapies, and regenerative medicine. The company's primary therapeutic focus is on the central nervous system (CNS), developing applications for nerve regeneration to treat conditions such as spinal cord injuries and cerebral infarctions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:30
Registration Form
有価証券届出書(組込方式)
Japanese 282.2 KB
2025-08-14 02:30
Interim Report
半期報告書-第9期(2025/01/01-2025/12/31)
Japanese 179.3 KB
2025-08-14 02:30
Interim Report
確認書
Japanese 8.8 KB
2025-03-28 02:01
Regulatory News Service
臨時報告書
Japanese 24.2 KB
2025-03-28 02:00
Regulatory News Service
内部統制報告書-第8期(2024/01/01-2024/12/31)
Japanese 22.4 KB
2025-03-28 02:00
Annual Report
有価証券報告書-第8期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2025-03-28 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-08-14 08:00
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 08:00
Interim Report
半期報告書-第8期(2024/01/01-2024/12/31)
Japanese 182.0 KB
2024-05-14 02:00
Quarterly Report
四半期報告書-第8期第1四半期(2024/01/01-2024/03/31)
Japanese 136.5 KB
2024-05-14 02:00
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-29 02:30
Post-Annual General Meeting Information
臨時報告書
Japanese 22.6 KB
2024-03-28 07:01
Registration Form
確認書
Japanese 8.8 KB
2024-03-28 07:00
Governance Information
内部統制報告書-第7期(2023/01/01-2023/12/31)
Japanese 22.4 KB
2024-03-28 07:00
Registration Form
有価証券報告書-第7期(2023/01/01-2023/12/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all K Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for K Pharma,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for K Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.